搜索
ADC Therapeutics SA
ADCT添加自选
1.070USD
-0.040-3.60%
收盘 09-11 16:00（美东）
135.08M总市值
亏损市盈率 TTM
盘后交易 19:00 (美东)1.070USD+0.005+0.47%
盘后交易 19:00 (美东)关于 ADC Therapeutics SA 公司
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
ADC Therapeutics SA 简介
公司代码ADCT
公司名称ADC Therapeutics SA
上市日期May 15, 2020
CEOMallik (Ameet)
员工数量263
证券类型Ordinary Share
年结日May 15
公司地址Biopole
城市EPALINGES
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家Switzerland
邮编1066
电话41216530200
网址https://adctherapeutics.com/
公司代码ADCT
上市日期May 15, 2020
CEOMallik (Ameet)
ADC Therapeutics SA公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
899.39K
+22.65%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
899.39K
+22.65%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
802.67K
+27.55%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
802.67K
+27.55%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
常见问题
ADC Therapeutics SA的前五大股东是谁？
ADC Therapeutics SA 的前五大股东如下：Mr. Ameet Mallik
有多少机构持有ADC Therapeutics SA(ADCT)的股份？
截至2026Q1，共有205家机构持有ADC Therapeutics SA的股份，合计持有的股份价值约为87.78M，占公司总股份的69.09%。与2025Q4相比，机构持股有所增加，增幅为-1768527.00。
哪个业务部门对ADC Therapeutics SA的收入贡献最大？
在2026Q1，Product业务部门对ADC Therapeutics SA的收入贡献最大，创收18.63M，占总收入的96.81%。